Hong Kong
· Delayed Price · Currency is HKD AIM Vaccine Statistics
Total Valuation
AIM Vaccine has a market cap or net worth of HKD 8.13 billion. The enterprise value is 9.79 billion.
| Market Cap | 8.13B |
| Enterprise Value | 9.79B |
Important Dates
The next estimated earnings date is Friday, November 29, 2024.
| Earnings Date | Nov 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AIM Vaccine has 1.21 billion shares outstanding. The number of shares has increased by 0.25% in one year.
| Shares Outstanding | 1.21B |
| Shares Change (YoY) | +0.25% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 28.20% |
| Owned by Institutions (%) | 7.82% |
| Float | 247.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.39 |
| PB Ratio | 2.16 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.66 |
| EV / Sales | 7.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -64.04 |
Financial Position
The company has a current ratio of 0.85, with a Debt / Equity ratio of 0.52.
| Current Ratio | 0.85 |
| Quick Ratio | 0.61 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | n/a |
| Debt / FCF | -13.78 |
| Interest Coverage | -33.51 |
Financial Efficiency
Return on equity (ROE) is -39.44% and return on invested capital (ROIC) is -17.66%.
| Return on Equity (ROE) | -39.44% |
| Return on Assets (ROA) | -14.13% |
| Return on Capital (ROIC) | -17.66% |
| Revenue Per Employee | 817,208 |
| Profits Per Employee | -821,151 |
| Employee Count | 1,624 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 3.55 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.94% in the last 52 weeks. The beta is -0.29, so AIM Vaccine's price volatility has been lower than the market average.
| Beta (5Y) | -0.29 |
| 52-Week Price Change | -36.94% |
| 50-Day Moving Average | 5.91 |
| 200-Day Moving Average | 7.07 |
| Relative Strength Index (RSI) | 49.10 |
| Average Volume (20 Days) | 3,843,308 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AIM Vaccine had revenue of HKD 1.27 billion and -1.28 billion in losses. Loss per share was -1.06.
| Revenue | 1.27B |
| Gross Profit | -704.41M |
| Operating Income | -1.97B |
| Pretax Income | -2.28B |
| Net Income | -1.28B |
| EBITDA | -1.82B |
| EBIT | -1.97B |
| Loss Per Share | -1.06 |
Balance Sheet
The company has 704.16 million in cash and 2.11 billion in debt, giving a net cash position of -1.40 billion or -1.16 per share.
| Cash & Cash Equivalents | 704.16M |
| Total Debt | 2.11B |
| Net Cash | -1.40B |
| Net Cash Per Share | -1.16 |
| Equity (Book Value) | 4.02B |
| Book Value Per Share | 3.11 |
| Working Capital | -465.48M |
Cash Flow
In the last 12 months, operating cash flow was -14.67 million and capital expenditures -138.16 million, giving a free cash flow of -152.83 million.
| Operating Cash Flow | -14.67M |
| Capital Expenditures | -138.16M |
| Free Cash Flow | -152.83M |
| FCF Per Share | -0.13 |
Margins
Gross margin is -55.36%, with operating and profit margins of -154.71% and -100.48%.
| Gross Margin | -55.36% |
| Operating Margin | -154.71% |
| Pretax Margin | -179.03% |
| Profit Margin | -100.48% |
| EBITDA Margin | -142.93% |
| EBIT Margin | -154.71% |
| FCF Margin | -12.01% |
Dividends & Yields
AIM Vaccine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.25% |
| Shareholder Yield | -0.25% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AIM Vaccine has an Altman Z-Score of 2.26. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.26 |
| Piotroski F-Score | n/a |